Cited by 696Cancer survivorship and careCancer-related cognitive impairment studiesHealth Systems, Economic Evaluations, Quality of Life

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrument

Esper, Peg, Mo, Fei, Chodak, Gerald, Sinner, Michael, Cella, David, Pienta, Kenneth J.·1997·Urology

DOI 10.1016/s0090-4295(97)00459-7

Open this paper in CoChat — free account

Abstract

Objectives As the incidence of prostate cancer in the United States exceeds 330,000 in 1997, increasingly more men are faced with treatment choices for which there is no clear approach. At every stage of disease, these treatment choices may involve clinically equivalent modalities that differ in side effects and impact upon quality of life (QOL). Comprehensive, yet efficient, questionnaires are needed to measure QOL in patients with prostate cancer.Methods Developed as a disease-specific adjunct to the Functional Assessment of Cancer Therapy (FACT) measurement system, a 12-item prostate cancer subscale (PCS) was developed and tested in three independent samples: a subscale development sample (n = 43), validity sample 1 (n = 34), and validity sample 2 (n = 96). The 12 items ask about symptoms and problems specific to prostate cancer. These questions are added to the general (FACT-G) instrument, thereby comprising a 47-item questionnaire.Results Internal consistency of the PCS ranged from 0.65 to 0.69, with coefficients for FACT-G subscales and aggregated scores ranging from 0.61 to 0.90. Concurrent validity was confirmed by the ability to discriminate patients by disease stage, performance status, and baseline prostate-specific antigen (PSA) level. Sensitivity to change in performance status and PSA score over a 2-month period suggested that some subscales of the FACT-Prostate (P) (including the PCS) are sensitive to meaningful clinical change.Conclusions Our findings support use of the FACT-P as a meaningful component of QOL evaluation in men undergoing therapy for prostate cancer.

Integrity signals

Registry

Crossref · 10.1016/s0090-4295(97)00459-7

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020
Self-citation
Cancer statistics, 1997
Parker, S. L., Tong, T., Bolden, S., & Wingo, P. A. (1997) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.47.1.5 · Cited by 2,000
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1756 · Cited by 1,575
Quality-of-life outcomes in men treated for localized prostate cancer
Litwin, M. S., Hays, R. D., Fink, A., Ganz, P. A., Leake, B., Leach, G. E., & Brook, R. H. (1995) · JAMA · doi:10.1001/jama.1995.03520260051032 · Cited by 1,020
Reliability and validity of the functional assessment of cancer therapy—lung (FACT-L) quality of life instrument
Cella, D. F., Bonomi, A. E., Lloyd, S. R., Tulsky, D. S., Kaplan, E. J., & Bonomi, P. (1995) · Lung Cancer · doi:10.1016/0169-5002(95)00450-f · Cited by 750
Self-citation
Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response.
Tannock, I. F., Gospodarowicz, M., Meakin, W., Panzarella, T., Stewart, L., & Rider, W. D. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.5.590 · Cited by 407
Quality-of-life outcomes in men treated for localized prostate cancer
Litwin, M. S. (1995) · JAMA · doi:10.1001/jama.273.2.129 · Cited by 281
The association of benign prostatic hyperplasia and cancer of the prostate
Bostwick, D. G., Cooner, W. H., Denis, L., Jones, G. W., Scardino, P. T., & Murphy, G. P. (1992) · Cancer · doi:10.1002/1097-0142(19920701)70:1+ · Cited by 222
Early Detection of Prostate Cancer
Scardino, P. T. (1989) · Urologic Clinics of North America · doi:10.1016/s0094-0143(21)01800-0 · Cited by 210
Quality of Life and Functional Status Measures in Patients With Head and Neck Cancer
DʼAntonio, L. L., Zimmerman, G. J., Cella, D. F., & Long, S. A. (1996) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.1996.01890170018005 · Cited by 197
Self-citation

Show all 22 references

Research works printed but not linked: 2

da Silva, 1993, Quality of life in patients with prostatic cancer. A feasibility study, Cancer, 71, 1138, 10.1002/1097-0142(19930201)71:3+<1138::AID-CNCR2820711436>3.0.CO;2-7 · DOI
Esper, 1995, FACT-P: a new instrument for quality of life evaluation in prostate cancer (abstract), J Urol, 153

Sorted by citations

Items 501–600 of 696

Acupuncture versus sham acupuncture and usual care for Antiandrogen-Induced hot fLashes in prostate cancer (AVAIL): study protocol for a randomized clinical trial
Qin, Z., Zang, Z., Yu, J., Lv, J., Li, N., Zhang, J., Yang, M., Kwong, J. S. W., Pang, R., Wang, J., et al. (2023) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-023-04218-y · Cited by 5
“It is a questionnaire used to assess the health-related quality of life in men with prostate cancer [21].”
Androgen Receptor Pathway Inhibitor Therapy for Advanced Prostate Cancer
Bastos, D. A., Soares, A., Schütz, F. A. B., Cronemberger, E. H., Luz, M. D. A., Martins, S. P. D. S., Muniz, D. Q. B., Cárcano, F. M., Smaletz, Ò., Peixoto, F. A., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.54253 · Cited by 5
An Evaluation of Time Spent Completing Electronically Collected Patient-Reported Outcomes in Clinical Trials
Andersen, L., Williams, M., Pease, S., Dhatt, H., & Delong, P. S. (2025) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-025-00767-1 · Cited by 5
CAVIPRES questionnaire as a measurement of quality of life in patients with prostate cancer in Spain: Daily clinical practice application
Gómez-Veiga, F., Cozar, J. M., Günthner, S., Pallás, M. P., Silmi-Moyano, A., & Rebollo, F. J. (2010) · Actas Urológicas Españolas (English Edition) · doi:10.1016/s2173-5786(10)70170-0 · Cited by 5
Patient‐reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial
Yokomizo, A., Koga, H., Ito, K., Takezawa, Y., Komiyama, M., Nishimura, K., Yonese, J., Hashine, K., Masumori, N., Arai, G., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.3895 · Cited by 5
Health-related Quality of Life of Patients Treated With Different Fractionation Schedules for Early Prostate Cancer Compared to the Age-standardized General Male Population.
Reinikainen, P., Lehtonen, M. J., Lehtinen, I., Luukkaala, T., Sintonen, H., & Kellokumpu-Lehtinen, P. (2022) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2022.07.013 · Cited by 4
Health-related quality of life in patients newly diagnosed with prostate cancer: CAPLIFE study
Lozano‐Lorca, M., Barrios‐Rodríguez, R., Redondo‐Sánchez, D., Cózar, J. M., Martín, M. A., García‐Caballos, M., Salcedo‐Bellido, I., Sánchez, M., Jiménez‐Moleón, J. J., & Olmedo‐Requena, R. (2022) · Quality of Life Research · doi:10.1007/s11136-022-03302-z · Cited by 5
Does sexual rehabilitation work for gay and bisexual prostate cancer patients? Acceptability, feasibility, and efficacy results from the Restore-2 randomized controlled trial
Rosser, B. R. S., Kohli, N., Bates, A. J., Talley, K. M., Wright, M. M., Polter, E. J., Wheldon, C. W., Haggart, R. C., Dickstein, D. R., Ross, M. W., et al. (2024) · Journal of Cancer Survivorship · doi:10.1007/s11764-024-01672-6 · Cited by 5
Protocol for a phase III RCT and economic analysis of two exercise delivery methods in men with PC on ADT
Alibhai, S. M. H., Ritvo, P., Mina, D. S., Sabiston, C. M., Krahn, M. D., TOMLINSON, G. A., Matthew, A., Lukka, H. R., Warde, P. R., Durbano, S., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4937-x · Cited by 6
Role, race, and place: Prostate cancer disparities in Patients' and Partners' health outcomes and psychosocial factors
Song, L., Keyserling, T. C., Chen, R. C., Ma, C., Xu, S., Shieh, K., Fuller, G. P., Nielsen, M. E., Northouse, L., Tan, X. M., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.5646 · Cited by 5
A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer
Macaulay, V. M., Lord, S., Hussain, S. A., Maroto, P., Jones, R. H., Climent, M. Á., Cook, N., Lin, C., Wang, S., Bianchini, D., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02380-1 · Cited by 5
“Three patients in the Xe1000 + En160 cohort had AEs leading to discontinuation of xentuzumab and enzalutamide.”
Background
Couples' Communication and Quality of Life during Prostate Cancer Survivorship.
Song, L. (2009) · Deep Blue (University of Michigan) · Cited by 5
Health-Related Quality of Life and Urolithiasis
Sharadin, C., & Lowry, P. S. (2017) · Springer eBooks · doi:10.1007/978-3-319-16414-4_2 · Cited by 5
Calidad de vida en pacientes con cáncer de próstata, operados de prostatectomía radical laparoscópica
Sierra-Guerra, K. L., Viveros-Contreras, C., Martínez-Carrillo, G., Hernández-León, O., & Caballero-Ambriz, G. (2014) · Revista Mexicana de Urología · doi:10.1016/s2007-4085(15)30027-6 · Cited by 5
“A pesar de su inclusión en los punta-jes de estudios clínicos, la calidad de vida sigue siendo una noción bastante variable, de Þ nido conceptual y operacio-nalmente de numerosas maneras 8 .”
Health‐related quality of life after prostate brachytherapy
Miller, N. L., & Theodorescu, D. (2004) · British Journal of Urology · doi:10.1111/j.1464-410x.2003.04989.x · Cited by 5
Assessing anxiety in Black men with prostate cancer: further data on the reliability and validity of the Memorial Anxiety Scale for Prostate Cancer (MAX-PC)
Nelson, C. J., Starr, T. D., Macchia, R. J., Hyacinthe, L., Friedman, S., & Roth, A. J. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-016-3092-7 · Cited by 14
Supported exercise TrAining for Men wIth prostate caNcer on Androgen deprivation therapy (STAMINA): study protocol for a randomised controlled trial of the clinical and cost-effectiveness of the STAMINA lifestyle intervention compared with optimised usual care, including internal pilot and parallel process evaluation
McNaught, E., Reale, S., Bourke, L., Brown, J. E., Collinson, M., Day, F., Hewison, J., Farrin, A. J., Ibeggazene, S., Innes, A. Q., et al. (2024) · Trials · doi:10.1186/s13063-024-07989-y · Cited by 4
Health-related quality of life with enzalutamide versus flutamide in castration-resistant prostate cancer from the AFTERCAB study
Uemura, H., Kobayashi, K., Yokomizo, A., Hinotsu, S., Horie, S., Kakehi, Y., Nonomura, N., Ogawa, O., Oya, M., Suzuki, K., et al. (2022) · International Journal of Clinical Oncology · doi:10.1007/s10147-022-02221-w · Cited by 4
Quality of life outcomes for patients with metastatic castration‐resistant prostate cancer and pretreatment prognostic score
Oyenuga, M., Halabi, S., Oyenuga, A., McSweeney, S., Morgans, A. K., Ryan, C. J., & Prizment, A. E. (2023) · The Prostate · doi:10.1002/pros.24503 · Cited by 4
Sleep health and quality of life in the Detroit Research on Cancer Survivors cohort
Trendowski, M. R., Ruterbusch, J. J., Baird, T. E., Kyko, J. M., Martin, J. L., Schwartz, A. G., Markey, G. E., Badr, M. S., & Beebe‐Dimmer, J. (2024) · Journal of Cancer Survivorship · doi:10.1007/s11764-024-01568-5 · Cited by 6
Patient Preference of Apalutamide Versus Enzalutamide for Recurrent or Metastatic Hormone-sensitive Prostate Cancer: An Open-label, Randomized, Crossover Trial
Ng, C., Yee, C.-H., Chiu, P. K., Wong, K. C. W., Lam, D. C. M., Yuen, V. W.-F., Lai, P.-T., & Teoh, J. Y. (2024) · European Urology Oncology · doi:10.1016/j.euo.2024.04.001 · Cited by 5
Physical activity, fatigue, kinesiophobia and quality of life: comparative study of prostate cancer survivors with healthy controls
Cihan, E., Karalezli, İ., Pirinççi, C. Ş., Çavdar, Ö. F., Göğer, Y. E., Aytar, A., & Karalezli, G. (2024) · BMJ Supportive & Palliative Care · doi:10.1136/spcare-2024-005239 · Cited by 4
Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer
Mehra, N., Antonarakis, E. S., Park, S. H., Goh, J. C. H., McDermott, R., González, N. S., Fong, P. C. C., Greil, R., Santis, M. D., Yanez, P. E., et al. (2025) · European Urology Oncology · doi:10.1016/j.euo.2025.04.018 · Cited by 4
Relationship between sexual function and prostate‐specific antigen bounce after iodine‐125 permanent implant brachytherapy for localized prostate cancer
Nishihara, K., Nakiri, M., Chikui, K., Suekane, S., Matsuoka, K., Hattori, C., Ogo, E., Abe, T., Matsumoto, Y., & Ishitake, T. (2014) · International Journal of Urology · doi:10.1111/iju.12411 · Cited by 4
Living with Bodily Changes in Hormone-Refractory Prostate Cancer
Lindqvist, O. (2011) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2011.07.009 · Cited by 4
Assessing the safety and feasibility of neoadjuvant hormone and radiation therapy followed by robot-assisted radical prostatectomy for treating locally advanced prostate cancer: protocol for an open-label, dose-escalation, single-centre, phase I clinical trial
Xiao, Y., Zhao, X., Chang, Y., Lu, X., Wang, Y., Zhang, H., & Ren, S. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-038678 · Cited by 4
Evaluation of health behaviors and overall quality of life in younger adult African American cancer survivors
Trendowski, M. R., Kyko, J. M., Lusk, C. M., Ruterbusch, J. J., Hastert, T. A., Harper, F. W. K., Thompson, H. S., Beebe‐Dimmer, J., & Schwartz, A. G. (2022) · Cancer Medicine · doi:10.1002/cam4.4855 · Cited by 3
2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial
Lehtonen, M., Sormunen, J., Luukkaala, T. H., Marttila, T. I., McDermott, R., Joensuu, T. K., Lehtinen, I., Ginman, C., & Kellokumpu‐Lehtinen, P. (2022) · Acta Oncologica · doi:10.1080/0284186x.2022.2098680 · Cited by 4
Health‐related quality of life the first year after a prostate cancer diagnosis a systematic review
Østergaard, L. D., Poulsen, M. H., Jensen, M. E., Lund, L. C., Hildebrandt, M. G., & Nørgaard, B. (2023) · International Journal of Urological Nursing · doi:10.1111/ijun.12340 · Cited by 4
Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial
Coletta, A. M., Simon, L. H., Maslana, K. E., Taylor, S., Larson, K., Hansen, P. A., Thomas, V. M., Ulrich, C. M., Kohli, M., Chipman, J., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12260-3 · Cited by 4
“The reliability coefficient of FACT-P is 0.87–0.89 [54].”
BackgroundInfluential
Correlates of health-related quality of life in African Americans diagnosed with cancer: a review of survivorship studies and the Detroit research on cancer survivors cohort
Trendowski, M. R., Ruterbusch, J. J., Baird, T. E., Wenzlaff, A. S., Pandolfi, S. S., Hastert, T. A., Schwartz, A. G., & Beebe‐Dimmer, J. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10200-y · Cited by 4
Data Pooling and Analysis to Build a Preliminary Item Bank
Eton, D. T., Lai, J., Cella, D. F., Reeve, B. B., Talcott, J. A., Clark, J. A., McPherson, C. P., Litwin, M. S., & Moinpour, C. M. (2005) · Evaluation & the Health Professions · doi:10.1177/0163278705275338 · Cited by 4
“…1996), the Prostate Cancer Treatment Outcome Questionnaire (PCTO-Q; Shrader-Bogen et al., 1997), the Functional Assessment of Cancer Therapy-Prostate (Esper et al., 1997), the Southwest Oncology Group (SWOG) QOL Questionnaire (Moinpour et al., 1998), the University of California–Los Angeles…”
MethodSelf-citation
Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer
Wada, Y., Kikuchi, K., Takahashi, W., Honda, J., Nakanishi, J., Matsumoto, K., Kuwahara, T., Kai, N., Kikukawa, H., & Ueda, S. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0445-4 · Cited by 4
“ment of cancer therapy-prostate), at baseline, and before chemotherapy cycles 2 and 4 [15, 16].”
Background
Combination therapy with VP16 and ethinylestradiol for hormone-refractory prostate cancer: good response with tolerability.
Azuma, H., Inamoto, T., Takahara, K., Ibuki, N., Koyama, K., Utimoto, S., Fujisue, Y., Uehara, H., Komura, K., Nomi, H., et al. (2010) · PubMed · Cited by 4
Design and Analysis of Quality-of-Life Data
Troxel, A. B., & Moinpour, C. M. (2012) · Chapman & Hall/CRC eBooks · doi:10.1201/b11800-26 · Cited by 4
High-intensity resistance and impact training for patients with hormone-sensitive prostate cancer and bone metastases—study protocol of a randomized clinical trial
Ragle, A., Mikkelsen, M. K., Vinther, A., Zerahn, B., Juhl, C. B., Theile, S., Madsen, K. S., Nielsen, D. L., & Østergren, P. B. (2025) · Trials · doi:10.1186/s13063-025-08937-0 · Cited by 3
“The FACT-P consists of 27 items from the Functional Assessment of Cancer Therapy–General that measure physical, social/ family, emotional, and functional well-being and 12 items that compose the PC Subscale [50].”
25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology
Dorff, T. B., O'Neil, B. B., Hoffman, K. E., Lin, D. W., Loughlin, K. R., & Dall’Era, M. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.04.016 · Cited by 3
Study protocol for the investigation of the clinical effectiveness of a physical activity behaviour change intervention for individuals living with and beyond cancer
Cantwell, M., Kehoe, B., Moyna, N. M., McCaffrey, N., Skelly, F., Loughney, L. A., Walsh, D. M. J., Dowd, K., McCarren, A. L., & Woods, C. B. (2022) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2021.100882 · Cited by 3
Patients' experiences of completing patient‐reported outcomes in clinical trials: An interview study
Østergaard, L. D., Nørgaard, B., Holm, M. E., Hansen, A., Lund, L. C., & Poulsen, M. H. (2023) · International Journal of Urological Nursing · doi:10.1111/ijun.12363 · Cited by 3
Multimedia-based hormone therapy information program for patients with prostate cancer: the result of a randomized pilot study
Chien, C.-H., Liu, K.-L., Chuang, C.-K., Wu, C.-T., Chang, Y.-H., & Yu, K.-J. (2023) · Scientific Reports · doi:10.1038/s41598-023-50006-6 · Cited by 3
Calidad de vida de pacientes con cáncer de próstata en tratamiento con bloqueo androgénico continuo vs intermitente: estudio prospectivo mediante la aplicación del cuestionario CAVIPRES
Labarta, C. R. S., Zalabardo, D. S., & Cárdenas, Á. D. P. (2015) · Anales del Sistema Sanitario de Navarra · doi:10.4321/s1137-66272015000200003 · Cited by 3
Anticancer Effect of Combination Therapy of VP16 and Fosfesterol in Hormone-Refractory Prostate Cancer
Azuma, H., Sakamoto, T., Kiyama, S., Ubai, T., Kotake, Y., Inamoto, T., Takahara, K., Nishimura, Y., Segawa, N., & Katsuoka, Y. (2008) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3181595af6 · Cited by 3
Symptoms predicting health-related quality of life in prostate cancer patients treated with localized radiation therapy
Hsiao, C., Chen, M. K., Meyers, K. J., & Saligan, L. N. (2017) · Family Medicine and Community Health · doi:10.15212/fmch.2017.0133 · Cited by 3
“The FACT-P was validated in numerous studies [30, 31], and is a well-established instrument with good reliability and validity [32–34].”
Method
Development and Initial Validation of the Novel Scale for Assessing Quality of Life of Prostate Cancer Patients Receiving Androgen Deprivation Therapy
Dun, Y., Liu, H., Yu, L., Li, Q., Zhang, X., Tang, X. A., Qin, C., & Xu, T. (2017) · Chinese Medical Journal · doi:10.4103/0366-6999.213416 · Cited by 3
Quality of life in patients diagnosed of prostate cancer treated with continuous androgen deprivation therapy vs. intermittent therapy
Labarta, C. R. S., Zalabardo, D. S., & Cárdenas, Á. D. P. (2015) · Anales del Sistema Sanitario de Navarra · doi:10.23938/assn.0068 · Cited by 3
The health-related quality of life in patients with prostate cancer managed with active surveillance using the Expanded Prostate Cancer Index Composite survey: Systematic review and meta-analysis
Abdelhafez, A., Hosny, K., EL-Nahas, A. R., & Liew, M. P. C. (2022) · Arab Journal of Urology · doi:10.1080/2090598x.2021.2024368 · Cited by 3
Effect of Qianlie Xiaozheng Tang, a Chinese herbal decoction, on castration resistant prostate cancer: A pilot study
Pang, R., Gao, X., Lu, J., & Zhang, Y. (2015) · African Journal of Traditional Complementary and Alternative Medicines · doi:10.4314/ajtcam.v12i6.3 · Cited by 3
Prostate cancer–Exercise and Metformin Trial (Pre-EMpT): study protocol for a feasibility factorial randomized controlled trial in men with localised or locally advanced prostate cancer
Hackshaw‐McGeagh, L., Robles, L. A., Persad, R. A., Rowe, E., Bahl, A. K., Aning, J. J., Koupparis, A. J., Abrams, P., Perks, C. M., Holly, J. M. P., et al. (2022) · Pilot and Feasibility Studies · doi:10.1186/s40814-022-01136-7 · Cited by 3
Pain, cancer-related distress, and physical and functional well-being among men with advanced prostate cancer
Walsh, E. A., Pedreira, P. B., Moreno, P. I., Popok, P., Fox, R. S., Yanez, B. R., Antoni, M. H., & Penedo, F. J. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-022-07453-0 · Cited by 4
Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 study
Wang, H., Jiang, S., Luo, H., Zhou, F., He, D., Ma, L., Guo, H., Liang, C. Y., Chong, T., Jiang, J., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02064-z · Cited by 3
Linking CHHiP prostate cancer RCT with GP records: A study proposal to investigate the effect of co-morbidities and medications on long-term symptoms and radiotherapy-related toxicity
Lemańska, A., Byford, R. C., Correa, A., Cruickshank, C., Dearnaley, D. P., Griffin, C. L., Hall, E., de Lusignan, S., & Faithfull, S. (2017) · Technical Innovations & Patient Support in Radiation Oncology · doi:10.1016/j.tipsro.2017.06.001 · Cited by 3
“PROs were collected (as previously described elsewhere [37,38]) with the UCLA Prostate Cancer Index (UCLAPCI) [39], Short Form (SF)-36 [40], and Functional Assessment of Cancer Therapy-Prostate (FACT-P) [41] questionnaires.”
MethodInfluential
Ensuring comprehensive assessment of urinary problems in prostate cancer through patient-physician concordance
Victorson, D. E., Brucker, P. S., Bode, R. K., Eton, D. T., Talcott, J. A., Clark, J. A., Knight, S. J., Litwin, M. S., Moinpour, C. M., Reeve, B. B., et al. (2013) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2012.09.006 · Cited by 3
“1 ) [23] 3”
Self-citation
Évaluation de la qualité de vie liée à la santé et des problèmes de santé prioritaires chez les patients atteints du cancer de la prostate : stratégie de définition du rôle des infirmières en pratique avancée
Bryant‐Lukosius, D., Browne, G. B., DiCenso, A., Whelan, T. J., Gafni, A., Neville, A. J., & Sathya, J. (2010) · Canadian Oncology Nursing Journal · doi:10.5737/1181912x201e1e11 · Cited by 2
Quality of life in patients with prostate cancer: development and application of a hybrid assessment method
Stone, P. C., Murphy, R. F., Matar, H. E., & Almerie, M. Q. (2008) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2008.28 · Cited by 3
Effectiveness of Traditional Chinese Medicine in Primary Care
Wong, W., Kuen, C. L. L., Tong, J. S. S., & Fong, D. (2012) · InTech eBooks · doi:10.5772/28899 · Cited by 3
Health-related quality of life in men with metastatic castration–resistant prostate cancer
Gee, A. L., Challapalli, A., & Bahl, A. K. (2015) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2015.1107479 · Cited by 3
Desarrollo y validación del primer cuestionario español de calidad de vida en pacientes con cáncer de próstata, basado en la percepción del paciente
Veiga, F. G., Olmo, J. M. C., Günthner, S., Pallás, M. P., Moyano, A. S., Ramos, E. B., & Rebollo, F. J. (2009) · Actas Urológicas Españolas · doi:10.4321/s0210-48062009000600004 · Cited by 3
Desarrollo de un cuestionario sobre la repercusión de los sofocos en la calidad de vida de los pacientes con cáncer de próstata avanzado. Estudio ESCAPA
Carballido, J., Tisaire, J. L., & Perulero, N. (2008) · Medicina Clínica · doi:10.1157/13119976 · Cited by 3
Dose-escalated radiotherapy for clinically localised and locally advanced prostate cancer
Daly, T., Hickey, B. E., See, A. M., & Francis, D. P. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012817 · Cited by 3
Re: Focal Therapy for Localised Unifocal and Multifocal Prostate Cancer: A Prospective Development Study
Walsh, P. C. (2012) · The Journal of Urology · doi:10.1016/j.juro.2012.07.089 · Cited by 3
834 Standardization in definitions in focal therapy for prostate cancer: Report from a Delphi consensus project
Postema, A. W., de Reijke, T. M., Ukimura, O., van den Bos, W., & de la Rosette, J. J. M. C. H. (2016) · European Urology Supplements · doi:10.1016/s1569-9056(16)60836-9 · Cited by 3
The Prostate cancer–Exercise and Metformin randomised controlled feasibility Trial (Pre-EMpT) in men following active surveillance, radical prostatectomy and radiotherapy
Robles, L. A., Hackshaw‐McGeagh, L., Aning, J. J., Bahl, A. K., Challapalli, A., Koupparis, A. J., Persad, R. A., Rowe, E., Shiridzinomwa, C., Martin, R. M., et al. (2025) · Pilot and Feasibility Studies · doi:10.1186/s40814-025-01654-0 · Cited by 2
“Quality of life was measured by the EQ-5D 5 level version (EQ-5D-5L) [27] and FACT-Prostate subscale (FACT-P) [28].”
Cross-cultural adaptation and psychometric validation of the Finnish version of the Expanded Prostate Cancer Index Composite-26 for patients with localised prostate cancer
Ettala, O. O., Bergroth, R., Riikonen, J. M., Boström, P. J., Koskimäki, J. E., Kuisma, J., Rannikko, A. S., Vaarala, M. H., Sanda, M. G., & Santti, H. (2025) · Scandinavian Journal of Urology · doi:10.2340/sju.v60.44371 · Cited by 2
Validation of the Brazilian Version of Functional Assessment of Cancer Therapy-Prostate—FACT-P (Version 4) in Prostate Cancer Patients
de Held, P. A., Matheus, W. E., Naccarato, A. M. E. P., Rodrigues, R. C. M., Ferruccio, A. A., & Ferreira, U. (2021) · Journal of Cancer Education · doi:10.1007/s13187-021-02024-z · Cited by 2
Cuestionario Español de Calidad de Vida en Pacientes con Cáncer de Próstata como medida de la calidad de vida de los pacientes con cáncer de próstata en España: aplicación a la actividad diaria
Gómez-Veiga, F., Cózar, J. M., Günthner, S., Pallás, M. P., Silmi-Moyano, A., & Rebollo, F. J. (2010) · Actas Urológicas Españolas · doi:10.4321/s0210-48062010000800005 · Cited by 2
UFO registry: final analysis of baseline data from patients with advanced prostate cancer in Asia
Ye, D., Kanesvaran, R., Chiong, E., Lojanapiwat, B., Pu, Y., Rawal, S. K., Aik, O. T., Zeng, H., Chung, B. H., Ashani, M. Y. N., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241293393 · Cited by 2
Cardiovascular training for fatigue in people with cancer
Wagner, C., Ernst, M., Cryns, N., Oeser, A., Messer, S., Wender, A., Wiskemann, J., Baumann, F. T., Monsef, I., Bröckelmann, P. J., et al. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015517 · Cited by 7
Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate Cancer
Matsubara, N., Petrylak, D. P., Ratta, R., Korbenfeld, E. P., Gafanov, R. A., Mourey, L., Todenhöfer, T., Gurney, H., Kramer, G., Bergman, A. M., et al. (2025) · European Urology Oncology · doi:10.1016/j.euo.2025.02.015 · Cited by 2
EFFECT OF QIANLIE XIAOZHENG TANG, A CHINESE HERBAL DECOCTION, ON CASTRATION RESISTANT PROSTATE CANCER: A PILOT STUDY
Pang, R., Gao, X., Lü, J., & Zhang, Y. (2015) · African Journal of Traditional Complementary and Alternative Medicines · doi:10.21010/ajtcam.v12i6.3 · Cited by 2
Health Outcomes Assessment in Cancer
Lawrence, W., & Clancy, C. M. (2003) · Disease Management & Health Outcomes · doi:10.2165/00115677-200311110-00003 · Cited by 2
Desarrollo del escap-cdv como instrumento de medida para la valoración de la calidad de vida en el cáncer de próstata. primera parte
López, A. M., Fibla, G. G., Martínez, P. C., Rodríguez, A. B., & Moreno, J. L. P. D. P. (2002) · Actas Urológicas Españolas · doi:10.1016/s0210-4806(02)72768-x · Cited by 2
PSA and Second-Line Therapy of Hormone Refractory Prostate Carcinoma
Serretta, V., Rizzo, I., Contino, G., Pavone, C., Pomara, G., Melloni, D., & Pavone‐Macaluso, M. (2001) · Urologia Internationalis · doi:10.1159/000056591 · Cited by 2
Evidence-Based Practice in Clinical Behavioral Oncology
Studts, J. L., Mejia, M. G., Kilkus, J. L., & Brothers, B. M. (2014) · Springer eBooks · doi:10.1007/978-0-387-09817-3_23 · Cited by 2
Validation in Spain of the Quality of Life questionnaire PROSQOLI in patients with advanced prostate cancer
Fernández-Arjona, M., la Cruz, G. D., Delgado, J. A., Malet, J., & Portillo, J. A. (2012) · Actas Urológicas Españolas (English Edition) · doi:10.1016/j.acuroe.2011.11.004 · Cited by 2
Psychosocial screening for patients with prostate cancer: The development and validation of the psychosocial distress questionnaire-prostate cancer
Castermans, E., Coenders, M., Beerlage, H. P., & Vries, J. D. (2016) · Journal of Psychosocial Oncology · doi:10.1080/07347332.2016.1233925 · Cited by 2
“…insomnia, masculinity problems, and sexual problems (Bisson et al., 2002; Cliff & Macdonagh, 2000; Couper et al., 2006; Eller et al., 2006; Esper et al., 1997; Eton, Lepore, & Helgeson, 2001; Hervouet et al., 2005; Kiss & Meryn, 2001; Kunkel, Bakker, Myers, Oyesanmi, & Gomella, 2000;…”
Principle Component Analysis of Health-Related Quality of Life Measures for Prostate Cancer
Kawahara, N., Hotta, Z.-U., Kanayama, M., NAGATA, M., Akaza, H., & Horie, S. (2016) · Juntendō Igaku/Juntendo igaku · doi:10.14789/jmj.62.472 · Cited by 2
Castrate-resistant prostate cancer: lessons learnt from a pilot study in the palliative care research population
Sullivan, K. A., Kingi, N., Good, P. D., Vayne-Bossert, P., & Hardy, J. R. (2018) · International Journal of Palliative Nursing · doi:10.12968/ijpn.2018.24.2.96 · Cited by 2
A Historical and Contemporary Review of Questionnaires Used in the Management of Post-Radical Prostatectomy Patients
Cooper, C. A., Sloan, M. J., Singh, A., Fantus, R. J., & Raheem, O. A. (2022) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2022.04.003 · Cited by 2
Improving quality of life in metastatic castration-resistant prostate cancer: the role of androgen receptor axis-targeted agents
Kuzma, M., Breznická, M., & Kliment, J. (2023) · Journal of Men s Health · doi:10.22514/jomh.2023.049 · Cited by 2
Étude de la qualité de vie dans les néoplasies ovariennes : outils et enjeux
Bryand, A., Hamidou, Z., Paget‐Bailly, S., Bonnetain, F., Mathelin, C., Baldauf, J., & Akladios, C. Y. (2015) · Gynécologie Obstétrique & Fertilité · doi:10.1016/j.gyobfe.2014.12.011 · Cited by 2
Att leva med kroppsliga förändringar vid obotlig cancersjukdom med fokus på prostatacancer : ”jag är frisk – bortsett från att jag har cancer som är dödlig, men det är liksom en annan sak”
Lindqvist, O. (2007) · KTH Publication Database DiVA (KTH Royal Institute of Technology) · Cited by 2
Effects of docetaxel on pain due to metastatic androgen-independent prostate cancer
Beer, T. M., & Bubalo, J. S. (2002) · Current Urology Reports · doi:10.1007/s11934-002-0070-z · Cited by 2
“Esper et al. [ 51 ] Fact-P A 39-item questionnaire composed of 27 "core" items and 12 items specific to prostate cancer, covering similar areas as the QLQ-C30 and QLM-P14.”
Method
Perspective on “Chemotherapy for Advanced Prostate Cancer: 25 Years Later”: Is It a Mirage or an Oasis?
Haines, I. E., & Stanley, R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.3319 · Cited by 2
The EAES Clinical Practice Guidelines on the Evaluation of Quality of Life After Laparoscopic Surgery (2004)
Korolija, D., Sauerland, S., Wood-Dauphinée, S., Abbou, C. C., Eypasch, E. P., Caballero, M. G., Lumsden, M. A., Millat, B., Monson, J. R. T., Nilsson, G., et al. (2006) · Springer eBooks · doi:10.1007/978-3-540-32784-4_1 · Cited by 2
Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer
Nelson, J. B., Carducci, M. A., Vogelzang, N. J., Sleep, D. J., Hulting, S. M., & Mulani, P. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.8095 · Cited by 2
Validating the Total Illness Burden Index for Prostate Cancer (TIBI-CaP) in Men with Castration-Resistant Prostate Cancer: Data from TRUMPET
Flanders, S. C., Kim, J., Wilson, S., Braziunas, J., Greenfield, S., Billimek, J., Lechpammer, S., Lin, D. W., Karsh, L. I., Quinn, D. I., et al. (2018) · Future Oncology · doi:10.2217/fon-2017-0438 · Cited by 1
Metastatic Prostate Cancer: An Update on Treatments and a Review of Patient Symptom Management
Drudge‐Coates, L., Delacruz, A., Gledhill, R., Goh, P., & Tomlinson, B. (2020) · Clinical journal of oncology nursing · doi:10.1188/20.cjon.369-378 · Cited by 1
Analysis of short-term quality of life in post-surgical androgen deprivation therapy in advanced prostate cancer: a comparison of bilateral sub-capsular orchidectomy and bilateral total orchidectomy
Arogundade, A. K., Ajape, A. A., Popoola, A. A., Abiola, O. O., & Biliaminu, S. A. (2022) · Rwanda medical journal · doi:10.4314/rmj.v79i1.2 · Cited by 1
“Also incorporated were the health performance status of the patients using Karnofsky performance status scale and a structured validated questionnaire: Functional Assessment of Cancer Therapy for Prostate cancer (FACT-PI version 4) [17] to assess each subject’s QoL post- orchidectomy.”
Method
Health-Related Quality of Life of Prostate Cancer Patients Receiving Care in Tertiary Hospitals in Ogun State
Olorunniyi, S. B., Olanrewaju, M., & N., O. C. (2024) · African Journal of Biology and Medical Research · doi:10.52589/ajbmr-rmdudccx · Cited by 1
Quality of Life Determinants in Patients with Metastatic Prostate Cancer: Insights from a Cross-Sectional Questionnaire-Based Study
Mittal, C., Gupta, H., Nagpal, C., Sahoo, R. K., Sharma, A., Gangadharaiah, B. B., Tansir, G., Panaiyadiyan, S., Shamim, S. A., Kaushal, S., et al. (2024) · Current Oncology · doi:10.3390/curroncol31090366 · Cited by 1
Psychosocial factors associated with perceived cognitive functioning in prostate cancer survivors: an exploratory cross-sectional analysis
Pembroke, L., Sherman, K. A., Dhillon, H. M., Francis, H., Gillatt, D. A., & Gurney, H. (2025) · Supportive Care in Cancer · doi:10.1007/s00520-025-09771-5 · Cited by 1
“Measures of functional well-being can encompass different aspects of a person’s daily functioning and participation, some of which may also be modifiable, such as sleep quality, sense of fulfilment, enjoyability and contentedness [43].”
Impact of PARP Inhibitors on Health-related Quality of Life in Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis
Roessler, N., Miszczyk, M., Matsukawa, A., Dematteis, A., Alfarhan, A. R., Cormio, A., Alqahtani, A. S., Rajwa, P., Schuettfort, V. M., Vetterlein, M. W., et al. (2025) · European Urology Open Science · doi:10.1016/j.euros.2025.08.008 · Cited by 1
“We included all prospective trial reports, including subset and post hoc analyses of the study groups, that evaluated HRQoL assessed using the EQ-5D-5L or FACT-P questionnaire [15,17].”
Anxiety and Health-related Quality of Life in Men with Prostate Cancer Undergoing Focal Therapy: A Prospective Single-arm Phase 2 Trial
Scherer, T. P., Lazos, A. G., Sonderer, J., Kaufmann, B., Schmid, F. A., Jenewein, J., Rupp, N. J., Moch, H., Eberli, D., & Mortezavi, A. (2025) · European Urology Focus · doi:10.1016/j.euf.2025.08.006 · Cited by 1
Quality of life assessment in patients with prostate cancer using the FACT-P questionnaire: linguistic and cultural adaptation of the Russian version
Zhuravlev, A. A., Shkolnik, M. I., Bogomolov, O. A., Kneev, A. Y., & Sukhanova, T. V. (2025) · Science and Innovations in Medicine · doi:10.35693/sim688641 · Cited by 1
Magnetic resonance-guided simultaneous multi-focal adaptive radiotherapy for prostate, pElvis & metastases (MRgSMART-PEM) in prostate cancer: a prospective phase II study
Sun, M., Qin, S.-R., Wei, R., Tian, Y., Yan, L.-L., Xia, W.-L., Liu, Z.-Q., Fu, Q., Song, Y.-W., Fang, H., et al. (2026) · Radiation Oncology · doi:10.1186/s13014-026-02799-9 · Cited by 1
“…using the IPSS [29], the Expanded Prostate Cancer Index Composite-26 (EPIC-26) [30], the Functional Assessment of Cancer Therapy-Prostate (FACT-P) [31], the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core-30 (EORTC QLQ-C30) [32], and the International…”
A Prolonged Nightly Fasting Plus Telehealth Coaching Intervention (PNF+) for Men on Androgen Deprivation Therapy for PCa: A Pilot Feasibility Randomized Controlled Trial
Wen, K., Freedman, J., Zarrabi, K. K., Slamon, R., Smith, R., Liang, J., Mille, P. J., Tester, W. J., & Kelly, W. K. (2026) · Nutrients · doi:10.3390/nu18071166 · Cited by 1
“The Functional Assessment of Cancer Therapy-Prostate Cancer (FACT-P) (Version 4) was administered to assess the quality of life in patients with PCa [20].”
An integrated lifestyle intervention for mitigation of adverse effects associated with androgen deprivation therapy for prostate cancer (STAMINA): a multicentre, randomised trial
Bourke, L., Rosario, D. J., Reale, S., Ibeggazene, S., Innes, A. Q., Scope, A., Price, G., Taylor, S. J., Steed, L., Sutton, E., et al. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(26)00304-9 · Cited by 1
Strategies Addressing Quality of Life: Management of Patient-Reported Outcomes and Symptoms
Paller, C. J., & Smith, T. J. (2014) · Current clinical urology · doi:10.1007/978-1-4939-1176-9_22 · Cited by 1
Urinary function and health-related quality of life of patients after laparoscopic radical prostatectomy: two methods of assessment for 112 patients with up to six years of follow-up
Kass‐Iliyya, A., Vasdev, N., Soomro, N., & Durkan, G. C. (2013) · Journal of Clinical Urology · doi:10.1177/1875974212465575 · Cited by 1
Clinical Implications of Measuring Quality-of-Life in Early Stage Prostate Cancer
Chang, P., Mehrdad Alemozaffar, A., & Sanda, M. G. (2012) · Humana Press eBooks · doi:10.1007/978-1-60761-259-9_19 · Cited by 1

Authors: Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K. J.
Affiliations: Rush University Medical Center (US)
Corresponding author: Esper, Peg
ORCID: Cella, David
Pienta, Kenneth J.
Venue: Urology
Publisher: Elsevier BV
Published: 1997-12
Volume: 50
Issue: 6
Pages: 920-928
ISSN: 0090-4295 (ISSN-L)
DOI: 10.1016/s0090-4295(97)00459-7
OpenAlex: W2004909463
Cited by: 696
References: 22
Citations by year: 2026: 18 · 2025: 22 · 2024: 34 · 2023: 25 · 2022: 45 · 2021: 34 · 2020: 20 · 2019: 31 · 2018: 35 · 2017: 29 · 2016: 33 · 2015: 30 · 2014: 28 · 2013: 31 · 2012: 27
FWCI: 4.00
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Urology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer survivorship and care
Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords: prostate cancer, quality of life, Functional Assessment of Cancer Therapy, questionnaire development, concurrent validity, internal consistency, sensitivity to change, prostate-specific antigen, performance status, disease stage
MeSH terms: Aged, Aged, 80 and over, Chicago, Humans, Male, Michigan, Middle Aged, Prostatic Neoplasms, Quality of Life, Surveys and Questionnaires, Sensitivity and Specificity, Reproducibility of Results

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrument

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Citations

Cites

Cited by

Related

Metadata

Record

About these checks